Shanghai, China, 24 July, 2024 — Recently, the Percutaneous Neuroprotection for Carotid Artery Remodelling (PCAR) Intervention System, jointly developed by MicroPort® NeuroTech™ in collaboration with Prof. Bo Yu's team at Fudan University Pudong Medical Center, achieved a global milestone with the completion of the world's first PCAR procedure at the center. This successful intervention rescued a patient suffering from severe carotid artery stenosis. The PCAR represents an evolution from Transcarotid Artery Revascularization (TCAR), further advancing minimally invasive techniques and simplifying operations.
Carotid artery stenosis is a major cause of ischemic stroke. Clinically, severe stenosis has traditionally been treated through Carotid Endarterectomy (CEA) and Carotid Artery Stenting (CAS). CEA involves surgical removal of the thickened arterial intima and atherosclerotic plaques through an incision in the carotid artery, but it is highly invasive and carries a higher risk of perioperative cardiac events. CAS, while less invasive, involves navigating a tortuous path through the femoral artery to the aortic arch and then to the carotid artery, which can increase the risk of intracranial embolism. To address these challenges, a new intervention method called TCAR was introduced. TCAR involves a small incision in the neck to connect a countercurrent cerebral protection device to the carotid artery and femoral vein, reversing blood flow from the brain through the carotid artery, filtering out dislodged plaques, and returning the blood to the body via the femoral vein. TCAR has become a mainstream intervention for carotid artery stenosis due to its shorter procedure time, simpler operation, and lower stroke risk.
Inspired by TCAR, MicroPort® NeuroTech™ and Prof. Bo Yu 's team successfully developed the PCAR system which allows for device placement through a simple puncture, thus making the procedure even less invasive. Moreover, PCAR serves as an important path and adjunct method for the endovascular intervention of cerebrovascular ischemic diseases.
Prof. Bo Yu remarked, "The successful procedure demonstrates that PCAR can be a vital method for the interventional treatment of cerebrovascular ischemic diseases. PCAR has opened a new pathway for interventional treatment of cerebrovascular diseases and has established a new platform for carotid and cerebrovascular interventions, which allows for further advancements in treatment capabilities, such as intravascular carotid plaque ablation to achieve EndoCEA."
About MicroPort® NeuroTech™
MicroPort® NeuroTech™ (MicroPort NeuroTech Limited; HKEX: 2172) , an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 120 cerebrovascular stenting procedures every day. In the future, MicroPort® NeuroTech™ will continue investing more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients.
More information is available at www.medneurotech.com.